Expanding Global Supportive Cancer Care Will Unlock Future Opportunities

Key Takeaways

• Expanding into new patient segments and global markets is fueling strong revenue growth and increasing adoption of PEDMARK® through strategic partnerships and investments.
  
• Positive regulatory developments and operational efficiencies are expected to improve margins, enable further product expansion, and support a move toward sustainable profitability.
  
• Heavy reliance on a single product, facing saturation, pricing pressures, competitive threats, and high operating costs could constrain revenue growth and increase financial risk.

Catalysts

Operates as a commercial stage biopharmaceutical company in the United States.

• The increasing prevalence of cancer due to an aging population is generating long-term demand for supportive care therapies like PEDMARK®, and Fennec's expanded market focus to include the much larger adolescent and young adult segment (AYA; ages 15–39) is now driving significant sequential revenue growth-potential for further revenue acceleration as more large oncology group accounts are penetrated and utilization deepens.
  
• Strengthened global healthcare spending and improved access to cancer therapies, particularly with international launches (e.g., the Norgine partnership in the EU and upcoming Japan study results/partnership), position the company for meaningful global revenue expansion and cash flow improvement through milestone payments and royalties in addition to direct product sales.
  
• Strategic investments in sales force, patient support programs, and peer-reviewed guideline endorsements (e.g., PQI for PEDMARK) are driving greater adoption and repeat usage within new and existing accounts, supporting durable top-line growth and enhancing operating leverage as commercial efficiency improves.
  
• Ongoing positive regulatory sentiment, including orphan drug support and favorable real-world data requirements, may facilitate future label expansions or additional indications for PEDMARK®, potentially opening new revenue streams and lengthening the product's lifecycle.
  
• Manufacturing and operational scale benefits are expected as sales grow, with anticipated second-half 2025 expense reductions and increasing topline momentum pointing to the likelihood of improving net margins and a path toward sustainable profitability.

Fennec Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Fennec Pharmaceuticals's revenue will grow by 44.6% annually over the next 3 years.
• Analysts assume that profit margins will increase from -36.1% today to 40.7% in 3 years time.
• Analysts expect earnings to reach $41.0 million (and earnings per share of $1.46) by about August 2028, up from $-12.0 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 12.1x on those 2028 earnings, up from -18.3x today. This future PE is lower than the current PE for the US Biotechs industry at 16.8x.
• Analysts expect the number of shares outstanding to grow by 1.46% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Fennec Pharmaceuticals Future Earnings Per Share Growth

Risks

• Fennec remains heavily dependent on a single commercial product (PEDMARK®); any clinical, regulatory, or market-based setbacks (such as adverse safety findings or competitive headwinds) with PEDMARK could have an outsized negative impact on revenue and earnings due to lack of product diversification.
  
• The company's addressable market size may face plateauing growth as PEDMARK® approaches saturation in its approved indications and geographic regions; any delay, failure, or slow progress in expanding indications, pipeline development, or international approvals could limit future revenue growth and long-term top-line expansion.
  
• Increasing global scrutiny and regulation of drug pricing, as highlighted by the pending final pricing processes in key EU markets (like Germany), introduce meaningful risk that Fennec may not be able to secure or maintain premium pricing abroad, putting downward pressure on revenue and net margins.
  
• Competition from compounded alternatives, especially in academic centers for pediatric patients, and the potential for future generic or biosimilar entrants once patent protection or exclusivity periods lapse, could erode PEDMARK®'s market share and impact both revenues and margins over time.
  
• The company's operating expense profile shows significant ongoing investment in commercialization, headcount, marketing, and intellectual property; if revenues do not scale as anticipated or milestone payments from partnerships (such as with Norgine or a potential Japan partner) are delayed or smaller than expected, Fennec may experience net losses, cash burn, and possible future dilutive capital raises, thereby pressuring long-term earnings and shareholder value.

Valuation

• The analysts have a consensus price target of $14.0 for Fennec Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $100.8 million, earnings will come to $41.0 million, and it would be trading on a PE ratio of 12.1x, assuming you use a discount rate of 6.8%.
  
• Given the current share price of $7.91, the analyst price target of $14.0 is 43.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.